EuroPCR 2018: Boston Scientific outlines its key presentations

186
Lotus

Boston Scientific Corporation has revealed its schedule of key presentations—including two late-breaking clinical trials—that will be featured at the 2018 EuroPCR (22–25 May, Paris, France) meeting. The late-breaking trials include the RESPOND trial, which provides two-year real-world outcomes for the Lotus transcatheter aortic valve implantation (TAVI) device, and this will be presented on 23 May (Wednesday).

In addition to the RESPOND trial, data for the Agent paclitaxel-coated balloon is also being presented.  These data are from a multicentre study of two drug-coated balloons in patients with arterial in-stent restenosis.

Other presentations that may be interest include two subanalyses from the REPRISE III randomised trial, also featuring the LOTUS valve, that are looking at the multivariate predictors of early and late stroke after implantation and gender-related differences in clinical presentation and outcomes after TAVI. Data regarding the matched comparison of anticoagulation vs. antiplatelet therapy after left atrial appendage closure with the Watchman device will also be presented.

Ian Meredith, executive vice president and global chief medical officer, Boston Scientific comments; “We feel that this year’s EuroPCR programme will serve as a backdrop for engaging dialogue around data milestones that demonstrate the strength of our cardiovascular portfolio. Additionally, we have been anticipating the outcomes from multiple studies being presented around our Synergy bioabsorbable polymer stent, including further insight into assessing outcomes associated with patients presenting with complex disease states, high bleeding risk and shorter dual antiplatelet regimens.”

Schedule of presentations:

22 May (Tuesday)

  • Insights from the randomised REPRISE III trial—multivariate predictors of early and late stroke after TAVI implantation; Room 342B, Level 3, 12.26pm
  • REPRISE III gender sub-analysis: Sex-related differences in clinical presentation and outcome after TAVI for severe aortic stenosis; Posters Lab, Level, 1.30pm

23 May (Wednesday)

  • RESPOND: 2 years clinical outcomes in patients treated with a repositionable and fully retrievable aortic valve in routine clinical practice; Room Maillot, Level 2, 9.36am
  • AGENT ISR: One-year outcomes from a randomized multicentre study of two drug-coated balloons for the treatment of coronary in-stent restenosis; Room Maillot, Level 2, 2.45pm

24 May (Thursday)

  • Propensity-matched comparison of anticoagulation vs. antiplatelet therapy after left atrial appendage closure with Watchman; Room 252B, Level 2, 2.45pm
(Visited 131 times, 5 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here